Literature DB >> 19499532

Neuropilin-1 is not a marker of human Foxp3+ Treg.

Pierre Milpied1, Amédée Renand, Julie Bruneau, Daniella A Mendes-da-Cruz, Sébastien Jacquelin, Vahid Asnafi, Marie-Thérèse Rubio, Elizabeth MacIntyre, Yves Lepelletier, Olivier Hermine.   

Abstract

Treg are immune cells that play a critical role in the regulation of the immune response. Although the transcription factor Foxp3 is widely accepted as the standard marker of Treg, specific surface markers are needed to better characterize these cells and decipher their mechanisms of action. Neuropilin-1 (Nrp-1), a membrane protein primarily involved in the nervous system, was identified as a specific marker of murine Treg, but its expression has not been rigorously investigated in human Treg. Here we show that in contrast to murine Treg and regardless of their origins (blood, thymus, spleen, lymph node or tonsil), human Foxp3(+) Treg do not specifically express Nrp-1. However, a population of Foxp3(-) Nrp-1(+) T cells can be detected in human secondary lymphoid organs, and Nrp-1 expression is induced on peripheral blood T lymphocytes upon in vitro activation. We conclude that Nrp-1 cannot be used as a specific marker of human Treg, but might represent a novel activation marker of human T cells both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19499532     DOI: 10.1002/eji.200839040

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  68 in total

1.  Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.

Authors:  Monika Edelbauer; Dipak Datta; Ingrid H C Vos; Aninda Basu; Maria P Stack; Marlies E J Reinders; Masayuki Sho; Katiana Calzadilla; Peter Ganz; David M Briscoe
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Regulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive?

Authors:  Song Guo Zheng
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

Review 3.  Harnessing regulatory T cells to suppress asthma: from potential to therapy.

Authors:  Alison N Thorburn; Philip M Hansbro
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-22       Impact factor: 6.914

Review 4.  TREG-cell therapies for autoimmune rheumatic diseases.

Authors:  Makoto Miyara; Yoshinaga Ito; Shimon Sakaguchi
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

Review 5.  Advances in distinguishing natural from induced Foxp3(+) regulatory T cells.

Authors:  Xiaohong Lin; Maogen Chen; Ya Liu; Zhiyong Guo; Xiaoshun He; David Brand; Song Guo Zheng
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

Review 6.  Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Authors:  Christopher G Mayne; Calvin B Williams
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

Review 7.  Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential.

Authors:  Charlotte Spitz; Holger Winkels; Christina Bürger; Christian Weber; Esther Lutgens; Göran K Hansson; Norbert Gerdes
Journal:  Cell Mol Life Sci       Date:  2015-10-30       Impact factor: 9.261

Review 8.  Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells.

Authors:  Prabhakaran Kumar; Shikha Saini; Saad Khan; Swarali Surendra Lele; Bellur S Prabhakar
Journal:  Cell Immunol       Date:  2018-09-29       Impact factor: 4.868

Review 9.  Regulatory T Cells: Central Concepts from Ontogeny to Therapy.

Authors:  Bernard Khor
Journal:  Transfus Med Rev       Date:  2016-07-26

Review 10.  Induced regulatory T cells in inhibitory microenvironments created by cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2014-06-17       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.